The CLEAR initiative was done in collaboration with TransCelerate BioPharma, the Association of Clinical Research Organizations (ACRO) and sponsors and CROs that were not members of either organization. "We were driven to action by stories of patients who waited for an opportunity to be on a potentially life-saving drug while a research contract was negotiated. One specific patient who caught our attention is TJ. View TJ's moving recollection of the realties some of our patients face and our moral responsibility as an industry to address the contract issue," said Christine Pierre, President of SCRS. "Patients deserve better than waiting for studies to start after taking more than 13 weeks for contracts to be completed, as is the current worldwide average."
The CLEAR working group will continue to meet and advocate for industry-wide adoption. Additionally, their next goal is finding a way to improve clinical research site contracts beyond North America. The white paper released during the Global Summit is available for complimentary download here.
SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS' mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clear-contract-clauses-announced-by-the-society-for-clinical-research-sites-300351632.html
SOURCE Society for Clinical Research Sites